TD Cowen analyst Ritu Baral raised the firm’s price target on Palvella Therapeutics (PVLA) to $133 from $97 and keeps a Buy rating on the shares. The target increase reflects the Ph2 CVM data update. Cowen increased QTORIN rapa’s PoS in CVM to 55%. Given the lack of spontaneous regression, similarities between the CVM-IGA and FDA accepted Ph3 MLM-IGA EP, they moved QTORIN rapa’s CVM launch year to 2029.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics granted FDA Fast Track Designation to QTORIN
- Palvella Therapeutics price target raised to $204 from $148 at Canaccord
- Buy Rating Affirmed for Palvella Therapeutics Following Promising Phase 2 TOIVA Trial Results
- Palvella Therapeutics price target raised to $174 from $110 at Chardan
- Palvella Therapeutics price target raised to $190 from $105 at Truist